The advent of immuno-oncology (IO) drugs profoundly changes our understanding of cancer biology as well as the management of patients at bedside. This is especially true for melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin's lymphoma or bladder cancer, for which these drugs already demonstrated substantial improvements in the patients' outcome. Beyond these indications, objective tumour responses have been reported in more than 20 different cancer types in early phase trials.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nCduBJ
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Point of view: Electrophysiological endpoints differ when comparing the mode of action of highly successful... Point of view: Electrophysiol...
-
Related Articles Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol:...
-
Abstract The core mission of the Early Stage Professionals in Molecular Imaging Sciences (ESPMIS) Interest Group is to help young scientist...
-
Abstract Background A reported penicillin allergy may compromise receipt of recommended antibiotic prophylaxis intended to prevent surgica...
-
In view of the performance requirements (e.g., ride comfort, road holding, and suspension space limitation) for vehicle suspension systems, ...
-
Background Moyamoya angiopathy (MMA) is characterised by a progressive stenosis of the terminal part of the internal carotid arteries and th...
-
Ravikiran N Pawar, Sambhunath Banerjee, Subhajit Bramha, Shekhar Krishnan, Arpita Bhattacharya, Vaskar Saha, Anupam Chakrapani, Saurabh Bhav...
-
Objectives A major measure of treatment success for drug users undergoing rehabilitation is the ability to enter the workforce and generate ...
-
Context. Despite improvement in pain management and availability of clinical treatment guidelines, patients in Jordan are still suffering fr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου